Kalytera Therapeutics Completes Acquisition of Talent Biotechs TSX Venture Exchange:KALY

  • Lead program in Graft versus Host Disease (“GvHD”), a life-threatening condition that can occur following stem cell or bone marrow transplantation
  • Four Phase 2 clinical studies evaluating CBD in the prevention and treatment of GvHD
  • Orphan drug designations (“ODD”) granted in the U.S. and Europe
  • Advancing towards FDA Phase 2b clinical studies

VANCOUVER, British Columbia, Feb. 16, 2017 (GLOBE NEWSWIRE) — Kalytera Therapeutics, Inc. (TSX-V:KALY) (“Kalytera”) announced today that it has successfully completed the previously announced acquisition (the “Acquisition”) of Talent Biotechs Ltd. (“Talent”), strengthening Kalytera’s position as an emerging market leader in cannabidiol (“CBD”) pharmaceuticals. Talent is a privately held, Israeli-based company evaluating the use of CBD to prevent and treat Graft versus Host Disease (“GvHD”).

“We feel incredibly fortunate to be continuing Talent’s groundbreaking work in GvHD,” said Andrew Salzman, M.D., Kalytera’s Chief Executive Officer. “There are currently

... read more at: https://globenewswire.com/news-release/2017/02/16/918075/0/en/Kalytera-Therapeutics-Completes-Acquisition-of-Talent-Biotechs.html